UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance
Updated Guidance Setting Out MHRA’s New Licensing Route Welcomed By Industry Bodies
Executive Summary
Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation. It has been warmly welcomed by the off-patent industry both locally and internationally.